- PRICING
- LIVE QUOTES
- LEARN
- HELP
More from Webull
Our Partners
EN
K
KNSA
Kiniksa Pharmaceuticals Internat…
59.20
+2.31+4.06%After Hours: 60.02 +0.82 +1.39%18:46 06/26 EDT
OPEN/PREV CLOSE57.42/56.89
TODAY RANGE56.56-59.77
VOL6.76M
MARKET CAP4.55B
52 WEEK RANGE26.27-61.12
AVG VOL (3M)770.44K
% TURNOVER8.78%
TURNOVER--
P/E (TTM)65.29
% RANGE5.64%
EPS(TTM)0.9067
P/E(FORWARD)48.52
P/B7.52
BVPS7.87
DIVIDEND--
P/S6.67
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP2.63B
SHARES OUTSTANDING76.94M
NEXT EARNINGS07/27-07/31
FREE FLOAT44.44M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Simply Wall St·1d ago
How Investors May Respond To Kiniksa (KNSA) Showcasing Uncommon Profitability In A Research‑Heavy Biotech Sector
Simply Wall St·06/19 11:22
Kiniksa (KNSA) Is Up 6.2% After Analyst Upgrade And Institutional Buying Surge - What's Changed
NASDAQ·06/18 09:05
New Strong Buy Stocks for June 18th
Simply Wall St·06/17 10:37
Kiniksa Pharmaceuticals International (KNSA) Stock Could Be 18% Undervalued After Strong Buy Upgrade
TipRanks·05/29 21:55
Kiniksa Shareholders Reelect Directors and Approve Auditor Mandates
PUBT·05/29 20:36
Kiniksa Pharmaceuticals held annual shareholder meeting
TipRanks·05/26 22:09
Kiniksa Pharmaceuticals Caps Major Shareholder Voting Control Rights
PUBT·05/08 17:30
Kiniksa Pharmaceuticals announces annual shareholder meeting
PUBT·05/08 17:30
Kiniksa publishes 2025 annual report
Simply Wall St·05/06 03:30
Why Kiniksa Pharmaceuticals (KNSA) Is Up 5.4% After Raising 2026 Revenue Guidance And What's Next
Simply Wall St·05/05 01:33
Assessing Kiniksa Pharmaceuticals (KNSA) Valuation After Strong Q1 Results And Raised Revenue Guidance
Same Industry
Name/Symbol
Change%
Price